{"id":"fluconazol","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Headache","drugRate":"13%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Dyspepsia","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Taste perversion","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Skin rash","drugRate":"1.8%","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"1.7%","severity":"common","organSystem":""}],"contraindications":["Congenital long QT syndrome","Disease of liver","Kidney disease","Pregnancy, function","Prolonged QT interval"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Fulminant hepatic failure","drugRate":"","severity":"serious"},{"effect":"Clinical hepatitis","drugRate":"","severity":"serious"},{"effect":"Cholestasis","drugRate":"","severity":"serious"},{"effect":"Anaphylactic reaction","drugRate":"","severity":"serious"},{"effect":"Angioedema","drugRate":"","severity":"serious"},{"effect":"Serum transaminase elevations >8x upper limit of normal","drugRate":"1%","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL106","moleculeType":"Small molecule","molecularWeight":"306.28"},"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Fluconazol","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:23:13.715268+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:23:19.266485+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fluconazol","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:23:19.780969+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Cytochrome P450 51 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:23:20.989330+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL106/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:23:20.648838+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"13184b13-e252-4b4d-a3e2-cfc4ad3d55b7","title":"FLUCONAZOLE TABLET [MAJOR PHARMACEUTICALS]"},"ecosystem":[],"mechanism":{"target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase"},"_scrapedAt":"2026-03-28T01:54:50.400Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:23:22.211864+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Candidal Urinary Tract Infection","diseaseId":"candidal-urinary-tract-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Candidal septicemia","diseaseId":"candidal-septicemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Candidal vulvovaginitis","diseaseId":"candidal-vulvovaginitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Candidemia","diseaseId":"candidemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Candidiasis of mouth","diseaseId":"candidiasis-of-mouth","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Candidiasis of the esophagus","diseaseId":"candidiasis-of-the-esophagus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Cryptococcal meningitis","diseaseId":"cryptococcal-meningitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Disseminated candidiasis","diseaseId":"disseminated-candidiasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Mucocutaneous candidiasis","diseaseId":"mucocutaneous-candidiasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Oropharyngeal Candidiasis","diseaseId":"oropharyngeal-candidiasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of Disseminated Candidiasis","diseaseId":"prevention-of-disseminated-candidiasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04988555","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)","status":"RECRUITING","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2022-02-28","conditions":"Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma","enrollment":606},{"nctId":"NCT07439250","phase":"PHASE1","title":"A Study of Olomorasib (LY3537982) in Healthy Participants","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-03-02","conditions":"Healthy","enrollment":15},{"nctId":"NCT05434104","phase":"NA","title":"The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study","status":"NOT_YET_RECRUITING","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2026-03","conditions":"Bacterial Vaginosis, Candida Vaginal","enrollment":114},{"nctId":"NCT05421858","phase":"PHASE3","title":"A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.","status":"RECRUITING","sponsor":"Basilea Pharmaceutica","startDate":"2024-12-11","conditions":"Candidemia, Candidiasis, Invasive","enrollment":450},{"nctId":"NCT04065399","phase":"PHASE1, PHASE2","title":"A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation","status":"RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2019-11-05","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia","enrollment":447},{"nctId":"NCT07396480","phase":"PHASE3","title":"Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-03-01","conditions":"Venentoclax, Myeloid Malignancies, Conditioning","enrollment":186},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT07395024","phase":"PHASE1","title":"A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-02-03","conditions":"Healthy Volunteer","enrollment":54},{"nctId":"NCT07044544","phase":"PHASE1","title":"Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-07-17","conditions":"Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT04368559","phase":"PHASE3","title":"Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mundipharma Research Limited","startDate":"2020-05-11","conditions":"Candidemia, Mycoses, Fungal Infection","enrollment":602},{"nctId":"NCT07396857","phase":"NA","title":"The Role of EDHFs on Blood Pressure Following a Bout of Prolonged Sitting","status":"RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2025-11-01","conditions":"Cardiovascular","enrollment":40},{"nctId":"NCT07342153","phase":"PHASE4","title":"Comparing the Efficacy of Oral Fluconazole Versus Oral Itraconazole in Treating Resistant Tinea Corporis","status":"RECRUITING","sponsor":"Urooj Fatima","startDate":"2025-11-01","conditions":"Tinea Corporis, Dermatophytosis","enrollment":126},{"nctId":"NCT07341672","phase":"PHASE1","title":"A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2026-03-04","conditions":"Healthy Adult Subject","enrollment":80},{"nctId":"NCT06666322","phase":"PHASE2, PHASE3","title":"Platform Trial For Cryptococcal Meningitis","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2025-05-28","conditions":"Hiv, Cryptococcal Meningitis","enrollment":2000},{"nctId":"NCT06489431","phase":"PHASE3","title":"Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rush University Medical Center","startDate":"2023-12-04","conditions":"Erectile Dysfunction, Penile Prosthesis; Complications, Infection or Inflammation","enrollment":200},{"nctId":"NCT07311759","phase":"PHASE3","title":"Safety and Efficacy of Intralesional 0.5% Triamcinolone Acetonide in 0.2% Fluconazole Solution vs 0.1% Topical Mometasone Furoate With 2% Miconazole Nitrate Cream in the Treatment of Chronic Paronychia: An Intraindividual Randomized Controlled Trial.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2024-08-17","conditions":"Chronic Paronychia","enrollment":21},{"nctId":"NCT07249346","phase":"PHASE2","title":"Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Hannah Choe, MD","startDate":"2026-06-01","conditions":"Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia","enrollment":124},{"nctId":"NCT07295314","phase":"EARLY_PHASE1","title":"Effect of Antifungals on the Intestinal Microbiome - a Randomized, Controlled, Proof-of-concept Trial","status":"NOT_YET_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2026-01","conditions":"Gut Microbiome, Healthy Adult Male, Antifungal Therapy","enrollment":50},{"nctId":"NCT05178862","phase":"PHASE3","title":"A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole","status":"TERMINATED","sponsor":"Scynexis, Inc.","startDate":"2022-08-03","conditions":"Candidiasis, Invasive, Candidemia","enrollment":68},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT03828773","phase":"NA","title":"PTX3-targeted Antifungal Prophylaxis","status":"RECRUITING","sponsor":"Bochud Pierre-Yves","startDate":"2019-02-11","conditions":"Candidiasis, Fungal Infection, Acute Myeloid Leukemia","enrollment":410},{"nctId":"NCT06774144","phase":"PHASE3","title":"Rezafungin Prophylaxis in Liver Transplant","status":"ENROLLING_BY_INVITATION","sponsor":"Fernanda P Silveira, MD, MS","startDate":"2025-10-15","conditions":"Liver Transplant Infection, Fungal Infection","enrollment":385},{"nctId":"NCT06274554","phase":"PHASE3","title":"Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2024-10-04","conditions":"Crohn's Disease, Inflammatory Bowel Diseases","enrollment":120},{"nctId":"NCT04498832","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-10-21","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":2100},{"nctId":"NCT06055257","phase":"PHASE3","title":"Combination Therapy: Hyperbaric Oxygen and PENTOCLO for Treatment of Osteoradionecrosis of the Mandible","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2025-01-16","conditions":"Osteoradionecrosis, Osteoradionecrosis of Jaw, Osteoradionecrosis of the Mandible","enrollment":24},{"nctId":"NCT02145832","phase":"PHASE2, PHASE3","title":"Fluconazole Versus Micafungin in Neonates With Candidiasis","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2014-10","conditions":"Candidiasis","enrollment":100},{"nctId":"NCT04078997","phase":"","title":"An Evaluation of PCV13 Vaccine Schedules, Comparing Impact of 2+1 vs 3+0 on Pneumococcal Carriage in Blantyre, Malawi","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2019-07-21","conditions":"13-valent Pneumococcal Vaccine, Streptococcus Pneumoniae","enrollment":3507},{"nctId":"NCT06414512","phase":"PHASE2","title":"Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2024-04-09","conditions":"Cryptococcal Meningitis","enrollment":48},{"nctId":"NCT06129734","phase":"PHASE1, PHASE2","title":"Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant","status":"RECRUITING","sponsor":"Benjamin Tomlinson","startDate":"2025-07-28","conditions":"Myeloid Malignancy, Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT07084584","phase":"PHASE1, PHASE2","title":"An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Galecto Biotech AB","startDate":"2026-06-10","conditions":"Relapsed/Refractory Acute Myeloid Leukemia (AML)","enrollment":184},{"nctId":"NCT06847464","phase":"PHASE1","title":"A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.","status":"COMPLETED","sponsor":"Enanta Pharmaceuticals, Inc","startDate":"2025-01-27","conditions":"RSV Infection, Drug Drug Interaction (DDI)","enrollment":48},{"nctId":"NCT07033962","phase":"NA","title":"Fractional CO₂ Laser or 40% Urea With Topical Fluconazole Microemulsion in Onychomycosis","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-06","conditions":"Onychomycosis","enrollment":40},{"nctId":"NCT05739682","phase":"NA","title":"Pain and Microbial Reduction of Antimicrobial Corticosteroid Mixture Versus Cryotherapy in Necrotic Teeth","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-07-01","conditions":"Dental Pulp Necrosis","enrollment":28},{"nctId":"NCT05426499","phase":"","title":"Translational PKPD Modeling of Anti-infective Drugs Used in Pediatric Units.","status":"RECRUITING","sponsor":"Poznan University of Medical Sciences","startDate":"2021-10-01","conditions":"Population Modeling of Anti-infective Drugs","enrollment":150},{"nctId":"NCT06345794","phase":"PHASE1","title":"A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants","status":"COMPLETED","sponsor":"DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company","startDate":"2024-04-03","conditions":"Healthy","enrollment":50},{"nctId":"NCT06922344","phase":"PHASE4","title":"Comparison of Efficacy of Oral Fluconazole Versus Oral Itraconazole in the Treatment of Pityriasis Versicolor","status":"RECRUITING","sponsor":"Khyber Teaching Hospital","startDate":"2025-03-01","conditions":"Pityriasis Versicolor","enrollment":106},{"nctId":"NCT06593457","phase":"PHASE1","title":"A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Nurix Therapeutics, Inc.","startDate":"2024-08-20","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT06822166","phase":"PHASE1","title":"Drug Interactions Trial of Methoxyethyl Etomidate Hydrochloride","status":"COMPLETED","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2023-12-04","conditions":"Interaction Drug Food","enrollment":68},{"nctId":"NCT06771063","phase":"PHASE2","title":"A Study of the Efficacy and Safety of WXSH0102 in Treating VCC Patients","status":"RECRUITING","sponsor":"Cisen Pharmaceutical CO., LTD.","startDate":"2025-01-13","conditions":"Vaginitis","enrollment":108},{"nctId":"NCT03135106","phase":"PHASE1","title":"A Study to Evaluate the Effect of Fluconazole and Itraconazole on Erdafitinib Pharmacokinetics in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-04-14","conditions":"Healthy","enrollment":54},{"nctId":"NCT06770530","phase":"PHASE4","title":"Introduction of Mycotic Prophylaxis At Cystectomy Trial.","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2024-06-24","conditions":"Cystectomy","enrollment":484},{"nctId":"NCT06765603","phase":"PHASE2","title":"Evaluating the Efficacy of the Combination of Multi-zonal Contact Lens and Atropine for Controlling Myopia Progression","status":"NOT_YET_RECRUITING","sponsor":"Singapore National Eye Centre","startDate":"2025-02-01","conditions":"Myopia","enrollment":180},{"nctId":"NCT06709196","phase":"PHASE4","title":"Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2025-01-07","conditions":"Cystectomy, Bladder Cancer Requiring Cystectomy, Postoperative Infections","enrollment":248},{"nctId":"NCT01058174","phase":"PHASE3","title":"Liver Transplant European Study Into the Prevention of Fungal Infection","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-12-15","conditions":"Liver Transplantation, Mycoses","enrollment":350},{"nctId":"NCT04551963","phase":"PHASE1","title":"Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies","status":"COMPLETED","sponsor":"BeiGene","startDate":"2020-11-15","conditions":"B-cell Malignancies","enrollment":26},{"nctId":"NCT06107829","phase":"PHASE4","title":"Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities","status":"WITHDRAWN","sponsor":"Stephen Ruedrich","startDate":"2025-01","conditions":"Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities","enrollment":""},{"nctId":"NCT01686607","phase":"","title":"Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2012-10-01","conditions":"Systemic Fungal Infections","enrollment":40110},{"nctId":"NCT05657613","phase":"PHASE1","title":"Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2023-01-03","conditions":"Drug Interactions","enrollment":60},{"nctId":"NCT01503515","phase":"PHASE3","title":"Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2013-03-21","conditions":"Fungal Infection, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":292},{"nctId":"NCT06616168","phase":"PHASE1","title":"Urogenital Infections in Women of Reproductive Age and the Activity of 4-Thiazolidinone Derivatives Against Pathogens","status":"ACTIVE_NOT_RECRUITING","sponsor":"Danylo Halytsky Lviv National Medical University","startDate":"2023-09-01","conditions":"Bacterial Vaginosis","enrollment":200},{"nctId":"NCT05076409","phase":"PHASE1","title":"A Study in Healthy Men to Test How Fluconazole Influences the Amount of BI 425809 in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-10-19","conditions":"Healthy","enrollment":15},{"nctId":"NCT04874441","phase":"NA","title":"Candida PCR Diagnosis Strategy in Patients From Intensive Care Units","status":"RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2022-05-19","conditions":"Candida","enrollment":120},{"nctId":"NCT05176379","phase":"PHASE4","title":"Endothelial Derived Hyperpolarization Factor and Vascular Control","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2022-02-19","conditions":"Healthy","enrollment":30},{"nctId":"NCT04495608","phase":"PHASE2","title":"Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Fluconazole in Hypercalcicuric Patients With Increased 1.25(OH) 2D Levels","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2021-01-13","conditions":"Nephrolithiasis, Nephrocalcinosis, Hypercalciuria","enrollment":56},{"nctId":"NCT05399641","phase":"PHASE3","title":"Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis","status":"COMPLETED","sponsor":"Scynexis, Inc.","startDate":"2022-05-01","conditions":"Vulvovaginal Candidiasis","enrollment":150},{"nctId":"NCT02244606","phase":"PHASE2","title":"Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis","status":"COMPLETED","sponsor":"Scynexis, Inc.","startDate":"2014-09","conditions":"Mycoses, Candidiasis, Invasive, Candidemia","enrollment":27},{"nctId":"NCT06173596","phase":"PHASE1","title":"A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-01-10","conditions":"Healthy","enrollment":60},{"nctId":"NCT00304772","phase":"PHASE4","title":"Fluconazole Versus Micafungin for Candida Bloodstream Infection in Non-Neutropenic Patients","status":"WITHDRAWN","sponsor":"Kyoto University","startDate":"2006-08","conditions":"Candidiasis, Sepsis","enrollment":""},{"nctId":"NCT06413056","phase":"PHASE4","title":"Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-10-20","conditions":"Neonatal Infection, Invasive Fungal Infections","enrollment":56},{"nctId":"NCT05795491","phase":"NA","title":"Blue Light Emitting Diode Therapy on Vulvovaginal Candidiasis","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-04-01","conditions":"Recurrent Vulvovaginal Candidiasis","enrollment":60},{"nctId":"NCT05543122","phase":"","title":"Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2022-03-09","conditions":"Breast Feeding","enrollment":39},{"nctId":"NCT02421068","phase":"","title":"Population PK/PD of Off Label Drugs in Premature Neonates","status":"COMPLETED","sponsor":"Sinno H.P. Simons","startDate":"2014-08","conditions":"Premature Birth","enrollment":246},{"nctId":"NCT05602597","phase":"PHASE1","title":"HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI","status":"COMPLETED","sponsor":"Hutchmed","startDate":"2022-06-01","conditions":"Relapsed or Refractory Lymphoma","enrollment":59},{"nctId":"NCT04930107","phase":"EARLY_PHASE1","title":"Vulvovaginal Candidiasis in Canadian Females","status":"RECRUITING","sponsor":"University of Manitoba","startDate":"2021-12-07","conditions":"Candidiasis, Vulvovaginal","enrollment":105},{"nctId":"NCT02765256","phase":"PHASE2","title":"Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2016-08","conditions":"Crohn's Disease","enrollment":8},{"nctId":"NCT05099367","phase":"NA","title":"Prostacyclin (PGI2) Pathway to Enhance Wound Healing in Diabetic Foot Ulcers","status":"UNKNOWN","sponsor":"University Hospital, Grenoble","startDate":"2021-10-01","conditions":"Diabetes Mellitus, Type 2, Diabetic Foot","enrollment":60},{"nctId":"NCT04038008","phase":"PHASE1","title":"Single Dose Crossover Comparative Bioavailability Study of Two Formulations of Fluconazole 200 mg in Healthy Adult Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Pharmtechnology LLC","startDate":"2019-07-26","conditions":"Bioequivalence","enrollment":26},{"nctId":"NCT06071650","phase":"NA","title":"Assessment, Monitoring and Optimisation of Prehabilitation Patients Using Wearable Fitness Trackers","status":"UNKNOWN","sponsor":"Imperial College London","startDate":"2023-02-27","conditions":"Cancer","enrollment":82},{"nctId":"NCT03734523","phase":"","title":"Clinical Trial to Survey Results of Flourish Vaginal Care System for Recurrent Bacterial Vaginosis","status":"COMPLETED","sponsor":"Vaginal Biome Science","startDate":"2021-07-01","conditions":"Bacterial Vaginosis, Vaginal Flora Imbalance","enrollment":38},{"nctId":"NCT03028103","phase":"PHASE1","title":"Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients","status":"COMPLETED","sponsor":"Epizyme, Inc.","startDate":"2017-03-27","conditions":"Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle Cell Lymphoma","enrollment":32},{"nctId":"NCT04029116","phase":"PHASE3","title":"Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)","status":"COMPLETED","sponsor":"Scynexis, Inc.","startDate":"2019-10-21","conditions":"Recurrent Vulvovaginal Candidiasis","enrollment":440},{"nctId":"NCT05895162","phase":"NA","title":"Zinc-containing Vaginal Gel and Oral Fluconazole for Vulvovaginal Candidiasis.","status":"UNKNOWN","sponsor":"FEMPHARMA Kft.","startDate":"2023-06-10","conditions":"Vulvovaginal Candidiasis, Vaginal Yeast Infections","enrollment":76},{"nctId":"NCT05862714","phase":"PHASE1","title":"Comparison of Efficacy of Single Oral Dose Fluconazole and Itraconazole in Patients With Pityriasis Versicolor","status":"COMPLETED","sponsor":"Combined Military Hospital Abbottabad","startDate":"2022-03-01","conditions":"Tinea Versicolor","enrollment":164},{"nctId":"NCT05367089","phase":"PHASE3","title":"The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms","status":"RECRUITING","sponsor":"Maastricht University Medical Center","startDate":"2022-08-22","conditions":"Candidiasis, Vulvovaginal, Recurrent Candidiasis of Vagina","enrollment":252},{"nctId":"NCT05848492","phase":"PHASE3","title":"Efficacy of Prophylactic Fluconazole Therapy in Preterm and Very Low Birth Weight Neonates in Preventing Invasive Fungal Infection.","status":"COMPLETED","sponsor":"Services Institute of Medical Sciences, Pakistan","startDate":"2021-05-01","conditions":"Invasive Candidiases","enrollment":110},{"nctId":"NCT03945448","phase":"PHASE2, PHASE3","title":"Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia","status":"RECRUITING","sponsor":"Makerere University","startDate":"2019-06-20","conditions":"Cryptococcal Meningitis","enrollment":356},{"nctId":"NCT05661591","phase":"PHASE1","title":"Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-02-28","conditions":"Malignant Tumor","enrollment":18},{"nctId":"NCT05775692","phase":"","title":"Population Pharmacokinetics of Fluconazole in the Treatment of Neonatal Fungal Infectious Disease","status":"UNKNOWN","sponsor":"Beijing Children's Hospital","startDate":"2020-01-01","conditions":"Fluconazole, Infection, Newborn","enrollment":150},{"nctId":"NCT03667690","phase":"PHASE3","title":"Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis","status":"COMPLETED","sponsor":"Cidara Therapeutics Inc.","startDate":"2018-10-07","conditions":"Candidemia, Mycoses, Fungal Infection","enrollment":199},{"nctId":"NCT00075803","phase":"PHASE3","title":"Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2003-11","conditions":"Lymphoma, Infection, Leukemia","enrollment":600},{"nctId":"NCT05147727","phase":"PHASE1","title":"Drug-drug Interaction Study Between Fluconazole and Famitinib in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-03-14","conditions":"Tumor","enrollment":22},{"nctId":"NCT02325011","phase":"PHASE1","title":"An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience.","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2014-11","conditions":"Healthy Subjects","enrollment":14},{"nctId":"NCT04933682","phase":"PHASE1","title":"Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2021-06-23","conditions":"Healthy","enrollment":16},{"nctId":"NCT05130723","phase":"","title":"Pharmacokinetics of Fluconazole in Children (2-18 Years)","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2022-10-18","conditions":"Invasive Fungal Infections","enrollment":30},{"nctId":"NCT00634166","phase":"PHASE4","title":"Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group","status":"TERMINATED","sponsor":"Mylan Inc.","startDate":"2007-09","conditions":"Burns","enrollment":220},{"nctId":"NCT04734405","phase":"PHASE2, PHASE3","title":"A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC)","status":"UNKNOWN","sponsor":"ProFem GmbH","startDate":"2019-10-01","conditions":"Recurrent Vulvovaginal Candidiasis","enrollment":432},{"nctId":"NCT05541107","phase":"PHASE3","title":"Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3","status":"UNKNOWN","sponsor":"Matinas BioPharma Nanotechnologies, Inc.","startDate":"2023-01","conditions":"Cryptococcal Meningitis","enrollment":270},{"nctId":"NCT05478772","phase":"PHASE1","title":"Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects","status":"COMPLETED","sponsor":"Concert Pharmaceuticals","startDate":"2022-07-11","conditions":"Health Volunteers","enrollment":18},{"nctId":"NCT05476731","phase":"","title":"Phenotypic and Genotypic Characterization of Malassezia Species Isolated From Malassezia Associated Skin Diseases","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-08","conditions":"Malassezia Infection","enrollment":100},{"nctId":"NCT05471063","phase":"NA","title":"Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-08-22","conditions":"Cryptococcal Meningitis","enrollment":30},{"nctId":"NCT05085171","phase":"PHASE3","title":"An Enhanced Package of Care to Reduce Reduce Mortality in Advanced HIV Disease","status":"RECRUITING","sponsor":"Makerere University","startDate":"2022-05-04","conditions":"The Study Will Focus on Assessing the Survival Benefit on an Enhanced Package of Care for Patients With Advanced HIV Disease","enrollment":2400},{"nctId":"NCT05059145","phase":"PHASE2","title":"A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2022-04-27","conditions":"Candidiasis, Vulvovaginal","enrollment":60},{"nctId":"NCT02329808","phase":"","title":"Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-06","conditions":"Hematologic Diseases, Oncology Problem, Kidney Diseases","enrollment":93},{"nctId":"NCT04532463","phase":"","title":"Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis","status":"COMPLETED","sponsor":"University of Pharmacy, Yangon","startDate":"2020-10-01","conditions":"Cryptococcal Meningitis","enrollment":30},{"nctId":"NCT02366884","phase":"PHASE2","title":"Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)","status":"UNKNOWN","sponsor":"Dr. Frank Arguello Cancer Clinic","startDate":"2011-07-26","conditions":"Neoplasms","enrollment":250},{"nctId":"NCT04773821","phase":"NA","title":"Performance of Prostate MRI and Following Biopsy to Detect Prostate Cancer Recurrence After Focal Therapy","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-06-02","conditions":"Prostate Cancer","enrollment":260},{"nctId":"NCT04464577","phase":"PHASE1","title":"A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2021-04-01","conditions":"Healthy Participants","enrollment":""},{"nctId":"NCT03476317","phase":"PHASE2","title":"Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2018-07-12","conditions":"Crohn Disease","enrollment":10},{"nctId":"NCT03840616","phase":"PHASE3","title":"Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections","status":"COMPLETED","sponsor":"Mycovia Pharmaceuticals Inc.","startDate":"2019-03-13","conditions":"Recurrent Vulvovaginal Candidiasis","enrollment":219},{"nctId":"NCT01869829","phase":"","title":"PEACE: Pediatric Antifungal Comparative Effectiveness","status":"COMPLETED","sponsor":"Duke University","startDate":"2015-01","conditions":"Pediatric Invasive Candidiasis","enrollment":750}],"_emaApprovals":[],"_faersSignals":[{"count":80,"reaction":"PYREXIA"},{"count":64,"reaction":"DRUG INTERACTION"},{"count":56,"reaction":"NEUTROPENIA"},{"count":50,"reaction":"FEBRILE NEUTROPENIA"},{"count":45,"reaction":"PNEUMONIA"},{"count":45,"reaction":"SEPSIS"},{"count":45,"reaction":"VOMITING"},{"count":44,"reaction":"FATIGUE"},{"count":43,"reaction":"THROMBOCYTOPENIA"},{"count":41,"reaction":"NAUSEA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL106"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":143,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Fluconazol","genericName":"Fluconazol","companyName":"Azienda Sanitaria-Universitaria Integrata di Udine","companyId":"azienda-sanitaria-universitaria-integrata-di-udine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:23:22.211864+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}